9 months ago
IONS
AnalystsDavid LebovitzDavid Lebovitz's Stock Forecasts
AnalystsDavid Lebovitz
Analyst Ranking
Top 12%
#608 out of 5298 analysts
Average Return
+10.76%
Win Rate
56%69 out of 124
Risk vs Reward
Poor
Good
David Lebovitz's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Clementia Pharmaceuticals IncCMTA | +202.87% | $8.70 | $26.35 | 2018-08-13 - 2019-04-17 | Strong Buy |
Cogent Biosciences IncCOGT | +164.77% | $12.49 | $33.07 | 2025-07-18 - 2026-06-16 | Strong Buy |
Ionis Pharmaceuticals IncIONS | +154.34% | $32.69 | $83.15 | 2025-02-20 - 2026-02-19 | Strong Buy |
Avexis IncAVXS | +129.75% | $94.81 | $217.83 | 2017-08-03 - 2018-05-15 | Strong Buy |
Cytokinetics IncCYTK | +126.51% | $33.04 | $74.84 | 2025-05-07 - 2026-05-06 | Strong Buy |
David Lebovitz Analyst Color
Get additional color on David Lebovitz's coverage of popular stocks
10 months ago
ALNY
10 months ago
IONS
10 months ago
ASND
a year ago
COGT
a year ago
BBIO
a year ago
ASND
a year ago
ALNY
a year ago
ALNY
3 years ago
SDGR
3 years ago
PLRX
4 years ago
ASND
David Lebovitz's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ionis Pharmaceuticals IncIONS | 12 | Strong Buy | $84.00 | +13.57% | Maintains | 9 months ago |
Cytokinetics IncCYTK | 4 | Strong Buy | $84.00 | +11.69% | Maintains | 10 months ago |
Alnylam Pharmaceuticals IncALNY | 25 | Strong Buy | $583.00 | +106.81% | Maintains | 10 months ago |
Celldex Therapeutics IncCLDX | 2 | Strong Buy | $48.00 | +48.51% | Maintains | 10 months ago |
Schrodinger IncSDGR | 8 | Hold | $20.00 | +33.96% | Downgrades | 10 months ago |
Ascendis Pharma AASND | 13 | Strong Buy | $290.00 | +25.43% | Maintains | 10 months ago |
Incyte CorpINCY | 6 | Strong Buy | $103.00 | +3.26% | Maintains | a year ago |
Viking Therapeutics IncVKTX | 2 | Hold | $38.00 | +28.16% | Maintains | a year ago |
Cogent Biosciences IncCOGT | 4 | Strong Buy | $22.00 | -33.47% | Maintains | a year ago |
Bridgebio Pharma IncBBIO | 5 | Strong Buy | $67.00 | +0.54% | Maintains | a year ago |
Blueprint Medicines CorpBPMC | 8 | Hold | $129.00 | N/A | Upgrades | a year ago |
Exelixis IncEXEL | 3 | Strong Buy | $56.00 | N/A | Maintains | a year ago |
Intellia Therapeutics IncNTLA | 8 | Hold | $10.00 | N/A | Maintains | a year ago |
Biomarin Pharmaceutical IncBMRN | 7 | Hold | $78.00 | N/A | Maintains | a year ago |
Pliant Therapeutics IncPLRX | 6 | Hold | $1.50 | N/A | Maintains | a year ago |
Madrigal Pharmaceuticals IncMDGL | 5 | Strong Buy | $469.00 | N/A | Maintains | a year ago |
Ptc Therapeutics IncPTCT | 9 | Strong Sell | $45.00 | N/A | Maintains | a year ago |
Crinetics Pharmaceuticals IncCRNX | 2 | Strong Buy | $74.00 | N/A | Maintains | 2 years ago |
Mirum Pharmaceuticals IncMIRM | 5 | Strong Buy | $68.00 | N/A | Maintains | 2 years ago |
Immuneering CorpIMRX | 2 | Hold | $12.00 | N/A | Maintains | 4 years ago |
Arcutis Biotherapeutics IncARQT | 5 | Strong Buy | $36.00 | N/A | Maintains | 4 years ago |
Syndax Pharmaceuticals IncSNDX | 1 | Hold | $21.00 | N/A | Maintains | 5 years ago |
Karyopharm Therapeutics IncKPTI | 3 | Strong Buy | $405.00 | N/A | Maintains | 5 years ago |
Ironwood Pharmaceuticals IncIRWD | 5 | Hold | $14.00 | N/A | Maintains | 5 years ago |
Tectonic Therapeutic IncTECX | 7 | Strong Buy | $300.00 | N/A | Maintains | 5 years ago |
Epizyme IncEPZM | 2 | Strong Sell | $5.00 | N/A | Downgrades | 5 years ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Strong Buy | $57.00 | N/A | Maintains | 5 years ago |
Macrogenics IncMGNX | 1 | Strong Sell | $15.00 | N/A | Maintains | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | $220.00 | N/A | Downgrades | 5 years ago |
Nabriva Therapeutics PLCNBRVF | 2 | Hold | $500.00 | N/A | Maintains | 6 years ago |
Zealand Pharma AZEAL | 1 | Strong Buy | $37.00 | N/A | Maintains | 6 years ago |
Clementia Pharmaceuticals IncCMTA | 2 | Strong Buy | $26.00 | N/A | Maintains | 8 years ago |
Avexis IncAVXS | 3 | Strong Buy | $129.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.